WHAT WE DO
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
Oct 14, 2021
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
BenevolentAI appoints Dr John Orloff to its Board of Directors
Sep 9, 2021
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Jul 9, 2021
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
May 5, 2021
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
Apr 8, 2021
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
Feb 11, 2021
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Data Diversity initiative
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy